GleamWall
中文EN

IXHL Incannex Healthcare Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873875 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY69.0%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.7%
ROA-19.9%
ROIC (approx.)-1,944.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio67.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q3*2025-03-312025Q22024-12-31
Income statement
Revenue$0———$0$0$0$12,000
R&D expense$1.12M$1.49M$321,000$2.28M$1.12M$3.70M$2.73M$1.41M
SG&A expense$2.31M$3.70M$3.73M$4.71M$5.67M$3.83M$2.27M$3.60M
Operating income-$3.44M-$5.19M-$4.05M-$7.00M-$6.79M-$7.53M-$5.00M-$5.00M
Interest expense———-$5,000-$5,000$0$132,000-$28,000
Pretax income-$1.94M-$2.49M-$3.88M-$6.52M-$6.41M-$31.60M-$3.97M-$5.89M
Income tax$0———$0———
Net income-$1.94M-$2.49M-$3.88M-$6.52M-$6.41M-$31.60M-$3.97M-$5.89M
EBITDA-$3.43M-$5.14M-$3.98M-$6.94M-$6.73M-$7.47M-$5.01M-$4.80M
EPS (basic)-0.15—-0.35-0.02-0.62—-6.19-0.33
EPS (diluted)-0.15—-0.35-0.02-0.62—-6.19-0.33
Weighted avg. shares (diluted)12.54M—12.35M349.46M10.34M—654,41817.62M
Balance sheet
Cash & equivalents$68.27M$67.71M$74.45M$68.90M$73.28M$15.04M$6.71M$2.10M
Current assets$70.23M$72.83M$80.09M$74.68M$78.30M$19.96M$15.63M$10.50M
PP&E, net$2,000$4,000$47,000$108,000$168,000$227,000$277,000$273,000
Total assets$70.39M$72.98M$80.28M$75.01M$78.72M$20.45M$16.20M$11.11M
Current liabilities$1.04M$1.49M$1.93M$1.55M$1.65M$6.98M$7.37M$5.84M
Short-term debt——————$1.40M$1.38M
Long-term debt———————$2.38M
Total debt———————$3.77M
Total liabilities$4.26M$5.61M$5.05M$1.60M$1.71M$7.06M$8.79M$10.14M
Shareholders' equity$66.14M$67.37M$75.23M$73.41M$77.01M$13.39M$7.40M$964,000
Net debt———————$1.67M
Shares outstanding12.54M12.54M13.68M359.22M347.71M6.48M17.79M17.79M
Cash flow statement
Operating cash flow$521,000$3.37M-$2.46M-$4.62M-$9.16M-$1.48M-$3.16M-$5.68M
Capital expenditure$0-$1,000$5,000$4,000$2,000$0$0—
Free cash flow$521,000$3.38M-$2.46M-$4.63M-$9.16M-$1.48M-$3.16M—
Investing cash flow-$54,000-$30,000-$18,000-$4,000-$42,000$0$0—
Financing cash flow$0-$6.91M$4.71M$927,000$67.18M$9.60M$7.74M$4.10M
Depreciation & amortization$2,000$50,000$65,000$59,000$66,000$61,000-$5,000$200,000
Stock-based compensation$312,000$1.19M-$1.47M-$2.28M$2.63M$1.30M-$416,000-$435,000
Share buybacks—$7.08M$1.14M—————

Free plan shows the latest 8 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.